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Abstract
Background—The increasing incidence of oropharyngeal cancer in many developed countries 
has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 
serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, 
characterization of HPV16 E6 seropositivity among individuals without cancer is warranted.
Methods—4,666 controls were pooled from several studies of cancer and HPV seropositivity, all 
tested within the same laboratory. HPV16 E6 seropositive controls were classified as having i) 
moderate (mean fluorescent intensity [MFI]≥484 & <1000) or ii) high seroreactivity (MFI≥1000). 
Associations of moderate and high HPV16 E6 seroreactivity with i) demographic risk factors; and 
seropositivity for ii) other HPV16 proteins (E1, E2, E4, E7 and L1) and iii) E6 proteins from non-
HPV16 types (HPV6, 11, 18, 31, 33, 45 and 52) were evaluated.
Results—Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with 
moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated 
with former smoking (odds ratio [OR] 5.5 [95% confidence interval [CI]:1.2-51.8]), and 
seropositivity against HPV16 L1 (OR 4.8, 95%CI:1.3-15.4); E2 (OR 7.7, 95%CI:1.4-29.1); 
multiple HPV16 proteins (OR 25.3, 95%CI:2.6-119.6 for 3 HPV16 proteins beside E6) and 
HPV33 E6 (OR 17.7, 95%CI:1.9-81.8). No associations were observed with moderate HPV16 E6 
seroreactivity.
Conclusions—High HPV16 E6 seroreactivity is rare among individuals without diagnosed 
cancer and was not explained by demographic factors.
Impact—Some HPV16 E6 seropositive individuals without diagnosed HPV-driven cancer, 
especially those with seropositivity against other HPV16 proteins, may harbor a biologically 
relevant HPV16 infection.
Keywords
human papillomavirus; HPV16 E6 antibodies; EPIC; ARCAGE; PLCO
Introduction
A rapid increase in the incidence of oropharyngeal cancer has been reported in many parts of 
the world with a high development index (1-8), especially among men younger than 60 
years of age (9). This upsurge has been attributed to an increase in HPV-driven 
oropharyngeal cancers (7). In the US, incidence has increased by more than 200% over the 
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past several decades (10). HPV16 infection alone accounts for approximately 90% of HPV-
positive oropharyngeal cancers (11, 12) and is estimated to be responsible for at least 50% 
of oropharyngeal cancer cases in parts of the world with a high development index (10, 13, 
14).
Unlike cervical cancer, a precursor lesion for oropharyngeal cancer has yet to be identified, 
making early detection of oropharyngeal cancers difficult (15). However, numerous case-
control studies have shown that the presence of circulating HPV antibodies is strongly 
associated with cancer of the oropharynx (12, 16-24). Recently, HPV16 E6 antibody 
positivity has been identified as a potentially promising marker for oropharyngeal cancer 
(25). A prospective study conducted with prediagnostic sera found that 35% of patients with 
oropharyngeal cancer were seropositive for HPV16 E6 compared to only 0.6% of controls; 
for some of the patients these antibodies were present more than 10 years prior to diagnosis 
and were not associated with cancers at other head and neck cancer sites (25). The 
specificity of HPV16 E6 marker for detection of oropharyngeal cancer makes biological 
sense considering that the oropharynx (unlike other anatomic sites of the head and neck) is 
rich in lymphoid tissue and therefore is more likely to induce an antibody response to HPV 
infection.
Due to the high specificity of HPV16 E6 seropositivity for oropharyngeal cancer, this 
marker has the potential to be further developed into a screening tool for identifying high-
risk individuals. Therefore, characterization of HPV16 E6 seropositivity within healthy 
individuals without diagnosed cancer is merited. However, HPV16 E6 seropositivity is 
extremely rare among healthy individuals without cancer (<1%), making it difficult to study 
(23-25).
To overcome this issue, we conducted a descriptive epidemiological analysis of pooled 
controls from several studies of cancer and HPV seropositivity whose samples were all 
tested within the same laboratory with a bridging panel that allowed for interpretation across 
studies (23-25). The goals of this analysis were to investigate demographic and serologic 
factors associated with HPV16 E6 seropositivity among individuals without diagnosed 
cancer.
Materials and Methods
Our analytic population consisted of 4,666 controls pooled from 4 large studies of HPV 
seropositivity; 3 studies of head and neck cancer and 1 study of anogenital cancers (23-26). 
Controls were pooled from i) two nested case-control investigations within the European 
Prospective Investigation Into Cancer and Nutrition (EPIC); one focused on head and neck 
cancer (n=1,599 controls) and one focused on HPV-driven anogenital cancers (n=718 
controls) (25, 26); ii) 1 nested case-control investigation within the Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial (PLCO) (n=924 controls; unpublished data); 
and iii) 1 case-control study, the Alcohol-Related Cancers and Genetic Susceptibility in 
Europe (ARCAGE) (n=1,425 controls) (23). Informed consent was obtained from all 
participants in each study, and each study was approved by their respective institutional 
ethics review boards.
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Description of Study Populations and Participant Selection
EPIC Cohort Study—In brief, 521,330 individuals were recruited to the cohort between 
1992 and 2000 from 10 European countries, of whom 385,747 contributed a blood sample 
(27). Participants completed self-administered questionnaires on lifestyle factors and diet. 
Two control participants (one in Denmark) were randomly assigned for each patient with 
cancer (including head and neck and anogenital cancers) from appropriate risk sets 
consisting of all cohort participants alive and free of cancer (except non-melanoma skin 
cancer) at the time of diagnosis (and hence, age) of the index case. Additional study specific 
matching criteria are discussed below.
EPIC Head and Neck Study: Matching criteria were: country, sex, date of blood collection 
(± 1 month, relaxed to ± 5 months for sets without available controls), and date of birth (±1 
year, relaxed to ± 5 years for sets without available participants). The final study included 
1,599 controls (25).
EPIC Anogenital Study: Matching criteria included: study center, sex, date of blood 
collection (± 3 months, relaxed to ± 6 months for sets without available controls), and age at 
blood collection (± 3 months, relaxed to ± 2 years for sets without available controls), 
fasting status, and where relevant, menopausal status, and postmenopausal hormone 
replacement therapy use, and menstrual cycle. The final study included 718 controls (26).
PLCO Cohort Study—PLCO recruited approximately 155,000 55-74 year-olds from the 
general population during 1993-2001 who had not been diagnosed previously with prostate, 
lung, colorectal, or ovarian cancer. Blood (screening arm only), demographic and behavioral 
data were collected (28). Blood samples were obtained at baseline and five subsequent 
annual visits; the earliest available sample was used for this study. For each case, four 
controls were randomly chosen from appropriate risk sets consisting of all cohort members 
alive and free of cancer (except non-melanoma skin cancer) at the time (and hence age) of 
diagnosis of the index head and neck cancer case. Matching criteria were: year of entry into 
the study, year the material was collected, study year of cancer diagnosis (for cases; the 
same year was used for the matched control), birth year, and smoking status (never, former, 
current) (unpublished data).
ARCAGE Case-Control Study—Briefly, 2,227 control subjects were recruited from 10 
European countries during the period from 2002 to 2005 using a standardized protocol in all 
centers (except France) (29). All subjects underwent personal interviews to record lifestyle 
exposures; details are described elsewhere (29). Controls were recruited in each center and 
frequency matched for age, sex, and area of residence to cases with head and neck cancer. 
ARCAGE centers mainly used hospital controls to facilitate collection of blood samples, 
with the exception of the UK centers which used population-based controls randomly 
chosen from the same family medical practice list as the corresponding cases. Hospital 
controls were selected from the following diagnoses: endocrine and metabolic, skin, 
subcutaneous tissue and musculoskeletal, circulatory, nervous system diseases, 
genitourinary, gastro-intestinal, ear, eye and mastoid, plastic surgery cases and trauma 
patients (23).
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Harmonization of Covariates
Given the variation between studies in how the covariates were ascertained, we were unable 
to create single unified definitions of smoking and alcohol consumption. As a result, 
individuals were categorized according to study-specific definitions of smoking and alcohol 
consumption (Supplemental Table 1).
Harmonization of Serologic Test Results
Plasma (EPIC and ARCAGE) and serum (PLCO) samples were sent on dry ice to the 
German Cancer Research Center (DKFZ, Heidelberg, Germany) and testing was performed 
using multiplex assays (24, 30-32). Samples were analyzed for HPV16 antibodies to the 
major capsid protein (L1), the early oncoproteins (E6, E7), and other early proteins (E1, E2, 
E4) with the exception of PLCO where seroreactivity against HPV16 E4 was not assessed. 
Additionally, seroreactivity against the E6 protein from the following HPV types was also 
evaluated; HPV6, HPV11, HPV18, HPV31, HPV33, HPV45 and HPV52 with the exception 
of the EPIC anogenital study where seroreactivity against HPV52 was not assessed. A 
bridging panel was included in all studies so that MFI values could be normalized to account 
for variation between assays. Briefly, this bridging panel consisted of a subset of 188 
samples with known seroprevalence for each HPV antigen as defined by standard MFI 
cutoffs. For each individual analysis, study-specific cut-off values were calculated for each 
antigen such that the seroprevalence of each HPV antigen within the bridging panel was the 
same across all studies. If the study-specific cutoff differed from the standard MFI cutoff by 
more than 10% for a particular antigen, the MFI values for that antigen were normalized by 
multiplying each value by the quotient of the standard MFI cutoff divided by the study-
specific MFI cutoff. This normalization allowed for the same standard MFI cutoff values for 
seropositivity to be applied across all three studies.
For HPV16 E6, two mutually exclusive categories of HPV16 E6 seroreactivity were created: 
i) moderate: MFI ≥ 484 and < 1000; and high: MFI ≥ 1,000. Previous work from our group 
showed that increasing the seropositivity cutoff of HPV16 E6 from 484 to 1000 resulted in 
an increased specificity for oropharyngeal cancer without an associated decrease in 
sensitivity (25). For the other HPV16 proteins the MFI cutoffs used to define seropositivity 
were: L1, 422; E1, 200; E2, 679; E4, 876; E6, 484; E7, 548. For the E6 proteins of non-
HPV16 types the MFI cutoffs for seropositivity were: HPV6 E6, 500; HPV11, 260; HPV18, 
243; HPV31, 890; HPV33, 253; HPV35, 260; HPV45, 249; HPV52, 271.
Statistical Analyses
Characteristics of the control participants were evaluated overall and by study. The 
proportion of HPV16 E6 seropositive controls by demographic categories was computed for 
the pooled studies. Demographic and serologic determinants of moderate and high HPV16 
E6 seroreactivity were evaluated through odds ratios (OR) and 95% confidence intervals 
(CI) calculated in univariate analyses by logistic regression. Demographic variables 
evaluated included: gender, age, world region, smoking status and alcohol consumption. 
Serologic variables evaluated included seroreactivity against: i) other HPV16 proteins (L1, 
E1, E2, E4, E7) and ii) E6 proteins from non-HPV16 types (HPV6, HPV11, HPV18, 
HPV31, HPV33, HPV45 and HPV52).
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Results
Participant Characteristics
A total of 4,666 controls without diagnosed cancer were included in this analysis (Table 1); 
1,425 (30.5%) individuals from ARCAGE; 2,317 (49.7%) from EPIC; and 924 (19.8%) 
from PLCO. The majority of the controls were male (63.7%), 60 years of age or younger 
(59.6%) and ever alcohol drinkers (80.3%); smoking status appeared evenly distributed 
among the categories (i.e.: never, former, current). Small differences between studies were 
noted for gender, age and smoking status (Table 1).
Demographic Determinants of HPV16 E6 Seropositivity
HPV16 E6 seropositivity was rare. Of the 4,666 pooled controls, a total of 32 individuals 
(0.7%) were seropositive for HPV16 E6. Prevalence of HPV16 E6 seropositivity was similar 
by study; ARCAGE (0.8%), EPIC (0.6%) and PLCO (0.9%). Of the 32 HPV16 E6 
seropositive controls, 17 (0.4%) were classified as having moderate HPV16 E6 
seropositivity (MFI ≥ 484 and < 1000) and 15 (0.3%) were classified as having high HPV16 
E6 seroreactivity (MFI ≥ 1000) (Table 2).
Age, gender, smoking status and alcohol consumption did not elevate the odds of moderate 
or high HPV16 E6 seroreactivity. Only former smoking was significantly associated with 
high HPV16 E6 seroreactivity, OR 5.5 (95% CI: 1.2-51.8). No other significant associations 
for either moderate or high HPV16 E6 seroreactivity were observed (Table 2).
Serologic Determinants of HPV16 E6 Seropositivity
Seroreactivity against HPV16 proteins, including L1, E1, E2, E4 or E7, was common. 
Similar seroprevalence for any of these proteins was observed among the HPV16 E6 
seronegative and moderately HPV16 E6 seroreactive controls; 27.9% and 29.4%, 
respectively (Table 3). No significant associations between moderate HPV16 E6 
seroreactivity and seroreactivity against any of the other HPV16 proteins either individually 
or combined was observed.
In contrast, prevalence of seroreactivity against 1 or more HPV16 proteins (L1, E1, E2, E4 
or E7) in addition to E6 was greatest among the controls with high HPV16 E6 seroreactivity; 
46.7%. Of the 5 HPV16 proteins evaluated, seroreactivity against HPV16 L1 was most 
common (n=5 out of 15, 33.3%). Controls with high HPV16 E6 seroreactivity were also 
more likely than HPV16 E6 seronegative controls to be seroreactive against all HPV16 
proteins with the exception of E7, however only HPV16 L1 (OR 4.3, 95% CI: 1.1-13.8) and 
E2 (OR 7.7, 95% CI: 1.4-29.1) reached statistical significance. High HPV16 E6 
seroreactivity was also significantly associated with seroreactivity against multiple HPV16 
proteins; OR 25.3 (95% CI: 2.6-119.6) for seroreactivity against 3 HPV16 proteins in 
addition to E6, although in absolute terms, seroreactivity against multiple HPV16 proteins 
was rare (4 of 4,666; 0.08%).
7.9% of HPV16 E6 seronegative controls were seroreactive against a non-HPV16 E6 protein 
compared to approximately 20% for both the moderate and high HPV16 E6 seroreactive 
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controls. Only seroreactivity for HPV33 E6 was significantly associated with high HPV16 
E6 seroreactivity; OR 17.7 (95% CI: 1.9-81.8, Table 4).
Discussion
In this large descriptive epidemiological analysis of more than 4,000 pooled controls from 
several studies of HPV seroreactivity and HPV-associated cancer (23-25), HPV16 E6 
seropositive controls were rare (<1%), particularly those with high HPV16 E6 seroreactivity 
(0.3%). Further, of the determinants of HPV16 seropositivity evaluated, significant 
associations were observed only among controls with high HPV16 E6 seroreactivity. Of the 
demographic risk factors assessed, none were predictors of HPV16 E6 seropositivity except 
for former smoking. Of the serologic determinants assessed, seroreactivity against other 
HPV16 proteins was common among all controls and was greatest among controls with high 
HPV16 E6 seroreactivity (47%). A marker of cumulative lifetime HPV16 exposure, HPV16 
L1 seropositivity (5 out of 15; 33.3%) was most commonly detected among high HPV16 E6 
seroreactive controls compared to the other 4 HPV16 proteins tested. High HPV16 E6 
seroreactivity was significantly associated with seroreactivity against HPV16 L1, E2 and 
multiple HPV16 proteins. Seropositivity for any non-HPV16 E6 proteins was less common; 
8% among HPV16 E6 seronegative controls and approximately 20% among controls with 
both moderate and high HPV16 E6 seroreactivity. Only HPV33 E6 seroreactivity was 
significantly associated with high HPV16 E6 seroreactivity, however due to its high 
sequence homology with the E6 protein of HPV16, this finding may be the result of 
antibody cross-reactivity (33).
Based on studies of cervical cancer (34), individuals without an underlying HPV-driven 
cancer would not be expected to have antibodies against the HPV16 oncoproteins. One 
potential explanation for the small percentage of controls with seroreactivity against HPV16 
E6 may be due to potential laboratory error or sample misclassification. Therefore, the 15 
strongly HPV16 E6 seroreactive controls identified may reflect the error rates within these 
large epidemiological studies. Alternatively, the HPV16 E6 seroreactive controls identified 
in our study may be harboring a yet to be diagnosed cancer or precancer. Recent findings 
have suggested that induction of HPV-specific antibodies, most notably HPV16 E6 
antibodies, may be a response to an underlying HPV-driven neoplastic process that may take 
years to manifest into a diagnosable cancer (25). Studies conducted at the time of diagnosis 
have shown that the presence of detectable HPV16-specific antibodies in diagnostic serum is 
highly sensitive for HPV-driven head and neck squamous cell carcinomas (35). A large 
proportion (7 out of 15) of controls with high HPV16 E6 seroreactivity was also seroreactive 
against at least one other HPV16 protein in addition to HPV16 E6. However, of all HPV16 
proteins, a recent prospective study showed that seroreactivity against HPV16 E6 is the most 
strongly associated with development of oropharyngeal cancer; OR 274 (95% CI: 110-681). 
Of note, all the HPV16 E6 seropositive oropharyngeal cancer cases identified in the 
previous study had HPV16 E6 MFI values greater than 1,000 and therefore would have been 
classified as having high seroreactivity in this current analysis (25). Taken together, these 
findings raise the possibility that the HPV16 E6 seropositive controls with high E6 
seroreactivity described in this study, especially those with antibodies against multiple 
HPV16 proteins, may be on the path to developing an HPV-driven cancer or precancer that, 
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as follow-up accrues may eventually be diagnosed. Updated record linkage of the EPIC head 
and neck cancer study (25) revealed that one HPV16 E6 seropositive control was 
subsequently diagnosed with invasive anal cancer, however, additional follow-up time is 
needed to fully investigate this possibility.
Therefore, an important limitation of this study is that we are unable to extend follow-up to 
further ascertain the health status of the HPV16 E6 seropositive controls. For the cohort 
studies (EPIC and PLCO), we will continue to monitor record linkage updates and 
investigate this question accordingly; for the ARCAGE case-control studies, no additional 
follow-up will become available. Additionally, controls in this analysis were initially 
matched to cases, therefore skewing their distribution of certain variables, such as age and 
gender, towards that of cases. For the case-control studies, controls were recruited only 
when they were eligible based on a list of non-chronic diseases unrelated to smoking and 
alcohol. While this does not jeopardize the validity of our findings, it limits their 
generalizability. There may have also been some minor misclassification in terms of 
smoking status and alcohol consumption due to the differences between studies in how these 
variables were ascertained on the questionnaires. Additionally, we do not have information 
regarding other covariates such as sexual behavior, and host immunogenetics, which may 
have been potentially helpful in explaining why some individuals develop these antibodies. 
Finally, even with over 4,000 pooled controls, we were still limited by power given that our 
outcome was so rare.
In conclusion, given the rarity of HPV16 E6 seropositivity among individuals without 
diagnosed cancer, our data suggests that HPV16 E6 serology results in an extremely low rate 
of misclassification among controls potentially implying that serology may have a higher 
specificity than other biomarkers in oropharyngeal cancer cases as well. Due to the high 
specificity of the HPV16 E6 marker (25), HPV16 E6 antibody testing may have the potential 
to identify individuals at high-risk for developing HPV-driven oropharyngeal cancer within 
a general population of older adults.
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